Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Arthritis & Rheumatism

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/art.27642PMID 20617520
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.

  2010cited by this paper
• Scleroderma.

  2009cited by this paper
• Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis

  2009cited by this paper
• Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.

  2009cited by this paper
• Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis.

  2009cited by this paper
• Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.

  2009cited by this paper
• Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts.

  2009cited by this paper
• The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis.

  2009cited by this paper
• Cannabinoid receptor CB1 antagonists state of the art and challenges.

  2009cited by this paper
• Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells

  2008cited by this paper
• Endogenous Cannabinoids: Structure and Metabolism

  2008cited by this paper
• Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis.

  2008cited by this paper
• Cannabinoid Receptors: Where They are and What They do

  2008cited by this paper
• Cannabinoid receptors and the regulation of bone mass

  2008cited by this paper
• Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis.

  2008cited by this paper
• Cannabinoids for cancer treatment: progress and promise.

  2008cited by this paper
• Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

  2008cited by this paper
• CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis

  2007cited by this paper
• Therapeutic potential of cannabinoid-based drugs.

  2007cited by this paper
• Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample.

  2007cited by this paper
• Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

  2007cited by this paper
• Systemic sclerosis: a prototypic multisystem fibrotic disorder.

  2007cited by this paper
• CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

  2006cited by this paper
• Peripheral cannabinoid receptor, CB2, regulates bone mass.

  2006cited by this paper
• Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells.

  2006cited by this paper
• Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.

  2006cited by this paper
• Systemic sclerosis: hypothesis-driven treatment strategies.

  2006cited by this paper
• Cannabinoid-based drugs as anti-inflammatory therapeutics

  2005cited by this paper
• Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

  2005cited by this paper
• Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors

  2005cited by this paper
• Fibrotic disease and the T(H)1/T(H)2 paradigm.

  2004cited by this paper
• Cannabinoid receptors and T helper cells.

  2004cited by this paper
• Fibrotic disease and the TH1/TH2 paradigm

  2004cited by this paper
• The endogenous cannabinoid system controls extinction of aversive memories

  2002cited by this paper
• Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis.

  2001cited by this paper
• Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).

  1999cited by this paper
• Molecular characterization of a peripheral receptor for cannabinoids

  1993influential reference
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990influential reference
• Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization.

  1988cited by this paper
• Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton.

  1976cited by this paper
• The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid.

  1961cited by this paper

• Activation of Cannabinoid Receptor 1 Enhances Wound Healing by Promoting the Proliferative Phase

  2026influential citation
• Characterizing the Role of Endocannabinoid Receptor Cnr1 in Mouse Ovarian Granulosa Cells

  2025cites this paper
• The endocannabinoid system as a therapeutic target in intestinal fibrosis

  2025cites this paper
• Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis.

  2025cites this paper
• Development of a human RPE In vitro model with AMD-like features reveals blue light-induced modulation of the endocannabinoid system.

  2025cites this paper
• Multi‐omics integration reveals a nonlinear signature that precedes progression of lung fibrosis

  2024cites this paper
• Anandamide is an Early Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis

  2024cites this paper
• Inhibition of the endocannabinoid system reverses obese phenotype in aged mice and partly restores skeletal muscle function.

  2023cites this paper
• Cannabinoid Analogue WIN 55212–2 Protects Paraquat-Induced Lung Injury and Enhances Macrophage M2 Polarization

  2022cites this paper
• Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases

  2022cites this paper
• Cannabidiol markedly alleviates skin and liver fibrosis

  2022influential citation
• Synthetic cannabinoids reduce the inflammatory activity of microglia and subsequently improve neuronal survival in vitro.

  2022cites this paper
• ACPA Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-β-Smad2/3 Signaling-Mediated Lung Fibroblast Activation

  2022cites this paper
• The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases

  2021influential citation
• The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases.

  2021cites this paper
• Peripheral Hybrid CB1R and iNOS Antagonist MRI-1867 Displays Anti-Fibrotic Efficacy in Bleomycin-Induced Skin Fibrosis

  2021influential citation
• Diabetes and Cannabinoid CB1 receptor deficiency promotes similar early onset aging-like changes in the skin.

  2021cites this paper
• EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice.

  2021cites this paper
• Targeting cannabinoid receptor 2 (CB2) limits collagen production—An in vitro study in a primary culture of human fibroblasts

  2021cites this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

  2021cites this paper
• Expression of the α7 Nicotinic Acetylcholine Receptor Is Critically Required for the Antifibrotic Effect of PHA-543613 on Skin Fibrosis

  2021cites this paper
• Both HuR and miR‐29s regulate expression of CB1 involved in infiltration of bone marrow monocyte/macrophage in chronic liver injury

  2020cites this paper
• "AM251, a cannabinoid receptor 1 antagonist, prevents human fibroblasts differentiation and collagen deposition induced by TGF-β - an in vitro study."

  2020cites this paper
• Cannabis in Dermatology

  2020cites this paper
• Biosynthesis, total synthesis, structural modifications, bioactivity, and mechanism of action of the quinone‐methide triterpenoid celastrol

  2020cites this paper
• Minimally Invasive Surgery for Chronic Pain Management: An Evidence-Based Approach

  2020cites this paper
• A new role for anandamide: defective link between the systemic and skin endocannabinoid systems in hypertrophic human wound healing

  2020cites this paper
• 2‐arachidonoylglycerol reduces chondroitin sulphate proteoglycan production by astrocytes and enhances oligodendrocyte differentiation under inhibitory conditions

  2020cites this paper
• Cutaneous endocannabinoid system: Does it have a role on skin wound healing bearing fibrosis?

  2020cites this paper
• The application of flax and hempseed in food, nutraceutical and personal care products

  2020cites this paper
• Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases

  2020cites this paper
• Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis

  2020cites this paper
• Medical cannabis and cannabinoids in rheumatology: where are we now?

  2019cites this paper
• Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

  2019cites this paper
• Cannabinoid derivatives acting as dual PPAR&ggr;/CB2 agonists as therapeutic agents for systemic sclerosis

  2019cites this paper
• Cannabinoids in the treatment of rheumatic diseases: Pros and cons.

  2019cites this paper
• Cannabis-Based Medicines and Medical Cannabis in Rheumatic Diseases: A Treasure Chest or Pandora’s box

  2019cites this paper
• Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis.

  2019cites this paper
• VCE‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐ and CB2 receptor‐dependent pathways

  2018cites this paper
• Cannabinoids for the treatment of rheumatic diseases — where do we stand?

  2018cites this paper
• The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders

  2018cites this paper
• EHP‐101, an oral formulation of the cannabidiol aminoquinone VCE‐004.8, alleviates bleomycin‐induced skin and lung fibrosis

  2018cites this paper
• Cannabinoid receptor types 1 and 2 and peroxisome proliferator‐activated receptor‐&agr;: distribution in the skin of clinically healthy cats and cats with hypersensitivity dermatitis

  2018cites this paper
• Frontiers of antifibrotic therapy in systemic sclerosis

  2018cites this paper
• Medical cannabis: A forward vision for the clinician

  2018cites this paper
• Abstract: Study of Retinochoroidal Circulation with Fluorescein Angiography after Whole Eye Transplantation in Rodents

  2018cites this paper
• Abstract: Replacement of Contracted Split-Thickness Skin Graft and Keloid Scar with a Self-Propagating Autologous Skin Construct (SkinTETM)

  2018cites this paper
• Cannabinoid Receptor 1 Mediates Homing of Bone Marrow‐Derived Mesenchymal Stem Cells Triggered by Chronic Liver Injury

  2017cites this paper
• Effects of JWH015 in cytokine secretion in primary human keratinocytes and fibroblasts and its suitability for topical/transdermal delivery

  2017cites this paper
• The role of cannabinoids in dermatology.

  2017cites this paper
• Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis

  2016cites this paper
• Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CB1 and CB2 Cannabinoid Receptors

  2016cites this paper
• Endocannabinoids and Skin Barrier Function: Molecular Pathways and Therapeutic Opportunities

  2016cites this paper
• From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology.

  2016cites this paper
• The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways

  2016cites this paper
• Brief Report of the Therapeutic Potential of Utilizing the Cannabinoid Receptor in Systemic Sclerosis (SSc)

  2015cites this paper
• Vitamin D receptor regulates TGF-β signalling in systemic sclerosis.

  2015cites this paper
• Endocannabinoid signaling at the periphery: 50 years after THC.

  2015cites this paper
• Protection from Radiation-Induced Pulmonary Fibrosis by Peripheral Targeting of Cannabinoid Receptor-1.

  2015cites this paper
• Cannabinoid receptor 1 is a major mediator of renal fibrosis.

  2015cites this paper
• Pathogenesis of Systemic Sclerosis

  2015cites this paper
• The Effect of Phytocannabinoids on Airway Hyper-Responsiveness, Airway Inflammation, and Cough

  2015cites this paper
• Fibrogenesis, novel lessons from animal models

  2015cites this paper
• Cannabinoid receptor 1 inhibition improves the intestinal microcirculation in experimental endotoxemia

  2014cites this paper
• Immune system: a possible nexus between cannabinoids and psychosis.

  2014cites this paper
• An investigation into the cannabinoid receptor type 2 as a therapeutic target for childhood cerebral hypoxia

  2013influential citation
• Targeted therapies for systemic sclerosis

  2013cites this paper
• Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities

  2012cites this paper
• Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1

  2012cites this paper
• The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis

  2012cites this paper
• Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis

  2012cites this paper
• Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm?

  2012cites this paper
• JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis.

  2012cites this paper
• MODULATION OF ENDOCANNABINOID SYSTEM IN EXPERIMENTAL ENDOTOXEMIA

  2012cites this paper
• New insights on chemically induced animal models of systemic sclerosis

  2011cites this paper
• Role of cannabinoid receptors and RAGE in inflammatory bowel disease.

  2011cites this paper
• Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis

  2011cites this paper